Oncology Research and Treatment最新文献

{"title":"Survivorship in Chimeric Antigen Receptor T-Cell Therapy Recipients: Infections, Secondary Malignancies, and Non-Relapse Mortality.","authors":"Tobias Tix, Marion Subklewe, Michael von Bergwelt-Baildon, Kai Rejeski","doi":"10.1159/000542631","DOIUrl":"10.1159/000542631","url":null,"abstract":"<p><strong>Background: </strong>Chimeric antigen receptor (CAR) T-cell therapy has significantly advanced the treatment of hematologic malignancies, offering curative potential for patients with relapsed or refractory disease. However, the long-term survivorship of these patients is marked by unique challenges, particularly immune deficits and infectious complications, second primary malignancies (SPMs), and non-relapse mortality (NRM). Understanding and addressing these risks is paramount to improving patient outcomes and quality of life.</p><p><strong>Summary: </strong>This review explores the incidence and risk factors for NRM and long-term complications following CAR T-cell therapy. Infections are the leading cause of NRM, accounting for over 50% of cases, driven by neutropenia, hypogammaglobulinemia, and impaired cellular immunity. SPMs, including secondary myeloid and T-cell malignancies, are increasingly recognized, prompting the FDA to issue a black box warning, although their direct link to CAR T cells remains disputed. While CAR T-cell-specific toxicities like cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome contribute to morbidity, they represent only a minority of NRM cases. The management of these complications is critical as CAR T-cell therapy is being evaluated for broader use, including in earlier treatment lines and for non-malignant conditions like autoimmune diseases.</p><p><strong>Key messages: </strong>CAR T-cell therapy has revolutionized cancer treatment, but survivorship is complicated by infections, SPMs, and ultimately endangered by NRM. Prophylactic strategies, close monitoring, and toxicity management strategies are key to improving long-term outcomes.</p>","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":" ","pages":"212-219"},"PeriodicalIF":2.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142676237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Highlights of Translational and Molecular Research Presented at the European Society for Medical Oncology Annual Meeting 2024.","authors":"Carolin Krekeler, Verena Turco, Annabel Helga Sophie Alig, Annalen Bleckmann, Michael Quante, Christoph Benedikt Westphalen, Kathrin Heinrich, Maryam Barsch","doi":"10.1159/000543566","DOIUrl":"10.1159/000543566","url":null,"abstract":"","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":" ","pages":"379-387"},"PeriodicalIF":2.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143625584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Palbociclib in Combination with either Aromatase Inhibitors or Fulvestrant for Patients with Advanced HR+/HER2- Breast Cancer in Germany: Final Results of the Phase 2 Multicohort INGE-B Trial.","authors":"Manfred Welslau, Karin Potthoff, Matthias Zaiss, Lothar Müller, Cosima Brucker, Christoph Salat, Michael Untch, Johannes Meiler, Diana Lüftner, Anja Welt, Steffen Dörfel, Volker Hagen, Alexander Stein, Rüdiger Liersch, Thomas Kuhn, Hans Ulrich Siebenbach, Gerlinde Bing, Corinne Vannier, Norbert Marschner, Katja Gratzke","doi":"10.1159/000542459","DOIUrl":"10.1159/000542459","url":null,"abstract":"<p><strong>Introduction: </strong>The INGE-B trial (NCT02894398) aimed to confirm the efficacy and safety data from the PALOMA trials for patients treated first line (1L) with palbociclib (PAL) and letrozole or 1L and later line with PAL and fulvestrant. In addition, so far lacking evidence for efficacy and safety on the combination of PAL with anastrozole, exemestane (1L), or letrozole (later line) was investigated.</p><p><strong>Methods: </strong>The prospective, multicenter, multicohort phase 2 trial INGE-B enrolled adult patients with locally advanced, inoperable, or metastatic HR+/HER2- breast cancer in Germany. The primary endpoint was the clinical benefit rate (CBR) in patients with measurable disease according to RECIST v1.1. Secondary endpoints were overall response rate, progression-free survival (PFS), overall survival (OS), safety, and quality of life. Data were analyzed with descriptive statistics.</p><p><strong>Results: </strong>Between 2016 and 2018, 388 patients were enrolled at 64 German sites. Among patients with measurable disease treated with PAL in 1L (n = 157), the CBR was 63.7% (100/157). Among all patients treated with PAL 1L (n = 219), PFS was 20.1 months (95% CI 14.6-24.0), and OS was 40.9 months (95% CI 35.1-49.2). The most common grade 3/4 adverse event was neutropenia (33.4% n = 77). There were no treatment-related deaths.</p><p><strong>Conclusion: </strong>The INGE-B trial demonstrated good efficacy and tolerability of PAL with letrozole (1L) or fulvestrant (first and later line) in accordance with the PALOMA trials. In addition, the so far lacking proof of efficacy and safety of PAL in combination with anastrozole or exemestane in 1L and with letrozole in later line was provided by INGE-B.</p><p><strong>Introduction: </strong>The INGE-B trial (NCT02894398) aimed to confirm the efficacy and safety data from the PALOMA trials for patients treated first line (1L) with palbociclib (PAL) and letrozole or 1L and later line with PAL and fulvestrant. In addition, so far lacking evidence for efficacy and safety on the combination of PAL with anastrozole, exemestane (1L), or letrozole (later line) was investigated.</p><p><strong>Methods: </strong>The prospective, multicenter, multicohort phase 2 trial INGE-B enrolled adult patients with locally advanced, inoperable, or metastatic HR+/HER2- breast cancer in Germany. The primary endpoint was the clinical benefit rate (CBR) in patients with measurable disease according to RECIST v1.1. Secondary endpoints were overall response rate, progression-free survival (PFS), overall survival (OS), safety, and quality of life. Data were analyzed with descriptive statistics.</p><p><strong>Results: </strong>Between 2016 and 2018, 388 patients were enrolled at 64 German sites. Among patients with measurable disease treated with PAL in 1L (n = 157), the CBR was 63.7% (100/157). Among all patients treated with PAL 1L (n = 219), PFS was 20.1 months (95% CI 14.6-24.0), and OS was 40.9 months (95% ","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":" ","pages":"14-25"},"PeriodicalIF":2.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11809519/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142650529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Critical Role of Sex and Gender in Medicine.","authors":"Kathrin Heinrich, Marie von Lilienfeld-Toal","doi":"10.1159/000542508","DOIUrl":"10.1159/000542508","url":null,"abstract":"","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":" ","pages":"1-3"},"PeriodicalIF":2.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142854762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Diagnostic Utility of cfDNA and ctDNA in Liquid Biopsies for Gastrointestinal Cancers over the Last Decade.","authors":"Nur Rahadiani, Marini Stephanie, Amelia Fossetta Manatar, Ening Krisnuhoni","doi":"10.1159/000543030","DOIUrl":"10.1159/000543030","url":null,"abstract":"<p><strong>Background: </strong>Cell-free DNA (cfDNA) is a fragmented DNA that is released into the blood through necrosis, apoptosis, phagocytosis, or active secretion. cfDNA includes a subclass called circulating tumor DNA (ctDNA) released from cancer cells and constitutes a varied proportion of the total cfDNA. Both cfDNA and ctDNA hold significant potential as diagnostic biomarkers in gastrointestinal cancers.</p><p><strong>Summary: </strong>cfDNA and ctDNA are promising diagnostic biomarkers for gastrointestinal cancers with varied diagnostic values in different types of cancers. cfDNA offers higher sensitivity that makes it more suitable for screening methods and constant monitoring, particularly in integration with conventional biomarkers or in a multimarker model. On the contrary, ctDNA gives a real-time picture of tumor genetics and is more suitable for definitive diagnosis due to its specificity for tumor-associated alterations. Different types of samples and methods of detection can influence sensitivity, and the amount of cfDNA is higher in serum but plasma is used for cfDNA analysis because it contains less cellular contamination. In summary, cfDNA is more sensitive than ctDNA, although they have comparable or slightly lower specificity.</p><p><strong>Key message: </strong>Further studies are needed to create common guidelines, minimize the cost of analysis, and perform extensive clinical trials to demonstrate the utility of circulating cfDNA and ctDNA in the vast majority of gastrointestinal cancer stages. Therefore, with the advancement in these technologies, cfDNA and ctDNA will be highly beneficial and evolve cancer diagnostics and therapy.</p>","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":" ","pages":"125-141"},"PeriodicalIF":2.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142838744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Advances in Metastatic Pancreatic Cancer Treatment in the Pre-Molecular Era: A Retrospective Single-Center Analysis 2010-2018.","authors":"Ralph Fritsch, Anina Julia Ruth Mäder, Saskia Hussung, Alexander Siebenhüner, Ralph Fritsch","doi":"10.1159/000546307","DOIUrl":"10.1159/000546307","url":null,"abstract":"&lt;p&gt;&lt;p&gt;&lt;p&gt;Introduction: Despite decades of extensive research, treatment options for pancreatic adenocarcinoma (PAC) patients kept limited, and prognosis remains dismal. For patients with metastatic PAC (mPAC), palliative combination chemotherapy remains the mainstay of treatment. Current treatment standards for mPAC have evolved from 2010 onwards with the introduction of combination chemotherapy protocols, the development of new chemotherapeutic agents, and the establishment of treatment sequences. Within our cohort, we analyzed the impact of different treatment options and sequences over time for mPAC patients in a Swiss academic center in the pre-molecular era between 2010 and 2018.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;This retrospective analysis included 97 patients who received palliative chemotherapy for mPAC between 2010 and 2018 at our institution. Outcome parameters, including median overall survival (mOS) and median progression-free survival (mPFS), were analyzed in the context of chemotherapy regimens and the number of treatment lines received. For comparative analyses, patients were separated into two groups, advancing to stage IV (metastatic) between 2010 and 2012, and between 2013 and 2018, respectively. Univariate analyses were performed via the log-rank test.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;For the entire cohort, mOS and first-line mPFS were 8.2 months (95% confidence interval [95% CI] 6.3-8.6 months) and 4.8 months (95% CI 3.4-5.8 months), respectively. When comparing between patients advancing to stage IV (metastatic) 2010-2012 and 2013-2018, the most frequent choice of systemic first-line therapy evolved from single-agent gemcitabine (GEM) toward the combination protocols FOLFIRINOX (FFX) and gemcitabine/nab-paclitaxel (GEM/nab-PTX). Moreover, the proportion of patients receiving further-line chemotherapies increased significantly between 2010-2012 and 2013-2018 (20 vs. 49% second-line treatment; p value [p] = 0.0035). Finally, a significant improvement in overall survival (OS) was observed for patients advancing to metastatic disease 2013-2018 compared to 2010-2012 (mOS 8.6 vs. 6.1 months; hazard ratio [HR] = 1.82; 95% CI 1.10-3.02, p = 0.0068). The use of combination regimens (FFX or GEM/nab-PTX) instead of GEM monotherapy as first-line systemic treatment was associated with a significantly improved OS (mOS 9.0 vs. 5.1 months; HR = 0.39; 95% CI 0.19-0.77, p = 0.0001) and first-line progression-free survival (PFS) (mPFS 5.0 vs. 4.7 months; HR = 0.57; 95% CI 0.32-1.03, p = 0.0213).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;In summary, systemic treatment of mPAC intensified during the study period with the availability of new first-line combination chemotherapy options and more lines of therapy. In parallel, patient survival improved, suggesting a causal relationship between more effective chemotherapy and improved outcome. Combination chemotherapy is standard of care for mPAC, while the future impact of molecular profiling and precision on","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":" ","pages":"614-623"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12173431/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144035299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Guidelines of Onkopedia: What Is New?","authors":"Magdalena K Scheck, Salah-Eddin Al-Batran, Markus Borner, Ines Gockel, Thorsten O Götze, Lars Grenacher, Holger G Hass, Dieter Köberle, Markus Moehler, Rainer Porschen, Ron Pritzkuleit, Holger Rumpold, Marianne Sinn, Martin Stuschke, Peter Thuss-Patience, Georg Maschmeyer, Bernhard Wörmann, Sylvie Lorenzen","doi":"10.1159/000546550","DOIUrl":"10.1159/000546550","url":null,"abstract":"<p><p>This article presents new relevant aspects of the recently updated German, Swiss, Austrian Onkopedia guideline for the treatment of esophageal cancer. The full guideline can be accessed at <ext-link ext-link-type=\"uri\" xlink:href=\"https://www.onkopedia-guidelines.info/en/onkopedia/guidelines/esophageal-cancer/@@guideline/html/index.html\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">https://www.onkopedia-guidelines.info/en/onkopedia/guidelines/esophageal-cancer/@@guideline/html/index.html</ext-link>. All rights for the use of text sections and figures have been obtained. The most important aspects in the perioperative treatment of resectable esophageal adenocarcinoma include the recommendation for the use of perioperative chemotherapy with FLOT as it was shown superior to preoperative chemoradiotherapy analogous CROSS in the ESOPEC trial. Furthermore, there is increasing evidence for the effectivity of targeting therapy and immune checkpoint inhibition in certain molecular defined subgroups. Immune checkpoint inhibition is recommended in combination with perioperative chemotherapy (FLOT) for MSI-H tumors, whereby the treatment should preferably take place in studies. In the metastatic setting, the approval for the PD-1 inhibitor tislelizumab was extended to the first-line treatment of both squamous cell carcinoma and adenocarcinoma of the esophagus (TAP score (≥5%) and for second line for squamous-cell cancer only (independent of PD-L1 expression). Moreover, for gastroesophageal junction (GEJ) tumors, pembrolizumab is available upon PD-L1 expression (CPS ≥1) according to the data of the KEYNOTE-859 trial. In addition to the established biomarkers HER2 und PD-L1, Claudin 18.2 represents now a new targetable option. First-line chemotherapy is to be combined with zolbetuximab in Claudin 18.2 positive GEJ tumors. For biomarker-negative adenocarcinomas of the esophagus and GEJ, a modified triplet regimen (TFOX) is a newly presented treatment option. Because of high toxicity rates and yet unclear survival benefit this option is only recommended for docetaxel-naïve patients with high remission pressure.</p>","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":" ","pages":"655-662"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144199766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Use of Follow-Up Psycho-Oncology Consultations in Urological Cancer after Transition from Inpatient to Outpatient Care.","authors":"Dominik Fugmann, Steffen Holsteg, Ralf Schäfer, Lars Kreuznacht, Daniela Speer, Günter Niegisch, Ulrike Dinger, André Karger","doi":"10.1159/000542458","DOIUrl":"10.1159/000542458","url":null,"abstract":"<p><strong>Introduction: </strong>In urological oncology, the physical and psychological effects of cancer and its treatment post-discharge highlight the importance of follow-up psycho-oncology consultations. This study examines their utilisation and identifies predictors in urological cancer patients after inpatient care.</p><p><strong>Methods: </strong>A prospective, single-centre clinical observational study was conducted. Inpatients with urological cancer and ≥5 points on the Distress Thermometer and/or request for psycho-oncological support were recruited, offered an initial psycho-oncology consultation, and can attend up to five online or on-site appointments within 3 months of discharge. The following variables were collected: socio-demographics, psycho-oncological baseline documentation (PO-BADO), psychosocial distress (Distress Thermometer with problem list), anxiety and depressive symptoms (GAD-2 and PHQ-2), and performance status (ECOG).</p><p><strong>Results: </strong>A total of 501 patients were screened, 139 were included, and 108 were analysed. Twenty five patients used psycho-oncological follow-up care (n = 16 online). The final hierarchical model predicting the use of follow-up psycho-oncological support included the two predictors: age (OR 0.93, 95% CI 0.90-0.96) and anxiety (OR 1.60, 95% CI 1.11-2.44).</p><p><strong>Conclusion: </strong>Nearly 1 in 4 urological cancer patients use follow-up psycho-oncology consultations, mostly online. Predictors for this usage are younger age and higher levels of anxiety. To improve care, (1) online services reduce barriers; (2) older patients require support with these services; and (3) screening specifically for depression is crucial to ensure that follow-up appointments are scheduled as a mandatory part of hospitalisation.</p><p><strong>Introduction: </strong>In urological oncology, the physical and psychological effects of cancer and its treatment post-discharge highlight the importance of follow-up psycho-oncology consultations. This study examines their utilisation and identifies predictors in urological cancer patients after inpatient care.</p><p><strong>Methods: </strong>A prospective, single-centre clinical observational study was conducted. Inpatients with urological cancer and ≥5 points on the Distress Thermometer and/or request for psycho-oncological support were recruited, offered an initial psycho-oncology consultation, and can attend up to five online or on-site appointments within 3 months of discharge. The following variables were collected: socio-demographics, psycho-oncological baseline documentation (PO-BADO), psychosocial distress (Distress Thermometer with problem list), anxiety and depressive symptoms (GAD-2 and PHQ-2), and performance status (ECOG).</p><p><strong>Results: </strong>A total of 501 patients were screened, 139 were included, and 108 were analysed. Twenty five patients used psycho-oncological follow-up care (n = 16 online). The final hierarchical model predi","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":" ","pages":"4-13"},"PeriodicalIF":2.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11809518/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142605897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality of Life of Cancer Patients in Routine Clinical Care Using the Example of Checkpoint Inhibition Therapy: A Delphi Consensus.","authors":"Philipp Ivanyi, Bernd Alt-Epping, Lars Bullinger, Anja Gesierich, Laura-Maria Krabbe, Urs Münch, Susanne Pfitzner-Dempfle, Christina Rieger, Achim Rittmeyer, Urban Wiesing, Martin Wolf, Ralf-Dieter Hofheinz, Philipp Ivanyi, Ines Vogel","doi":"10.1159/000545513","DOIUrl":"10.1159/000545513","url":null,"abstract":"<p><p><p>Introduction: The introduction of immune checkpoint inhibitors (CPIs) in oncology has improved the long-term perspectives of many patients and is bringing the quality of life (QoL) into focus as a treatment-relevant variable. In clinical routine, standardized and reliable tools for collecting, understanding, and utilizing QoL information are needed. In the current work, an interdisciplinary consensus on aspects of QoL in standard clinical practice has been put forth.</p><p><strong>Methods: </strong>After independent, structured individual interviews with members of an interdisciplinary expert panel (n = 12), ten theses on QoL with particular consideration regarding CPI therapy were drafted. These formed the basis of a multistage, independent, anonymous, externally commented, qualitative Delphi process. During the period May - December 2022, the panel developed interdisciplinary consensus recommendations for recording QoL and its role in decision-making in everyday care.</p><p><strong>Results: </strong>Out of ten theses, five recommendations arranged into three subject areas were agreed upon. QoL is considered a multifactorial and dynamic parameter that goes far beyond treatment-associated side effects. Mindful communication with the patient is considered the basis for QoL assessment and QoL modification. In everyday clinical practice, QoL should be documented and assessed in a structured, regular, and individualized way, thereby providing a basis for decisions on treatment options.</p><p><strong>Conclusion: </strong>The individual QoL of cancer patients should be assessed before and throughout therapy. Especially for long-term responders of CPI therapy and in the adjuvant setting, QoL appears to be treatment relevant. The recommendations based on the Delphi method provide practical assistance. </p>.</p>","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":" ","pages":"498-505"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12101803/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143803786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Highlights from ESMO 2024 as a Young Head and Neck Oncologist.","authors":"Mahdi Yassine, Gerald Illerhaus, Dennis Hahn","doi":"10.1159/000545872","DOIUrl":"10.1159/000545872","url":null,"abstract":"","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":" ","pages":"555-557"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144006626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}